STSA

Satsuma Pharmaceuticals, Inc. Common Stock

Delisted

STSA was delisted on the 7th of June, 2023.

32 hedge funds and large institutions have $94.2M invested in Satsuma Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
32
Holders Change
-4
Holders Change %
-11.11%
% of All Funds
0.54%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
9
Reduced
8
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Shares
Change %
Two Sigma Investments
26
Two Sigma Investments
New York
$57K -$156K -37,405 -73%
Charles Schwab
27
Charles Schwab
California
$52K
SSA
28
Schonfeld Strategic Advisors
New York
$47K -$41.6K -10,100 -47%
Goldman Sachs
29
Goldman Sachs
New York
$42K -$108 -26 -0.3%
Citigroup
30
Citigroup
New York
$29K +$29K +7,073 New
Osaic Holdings
31
Osaic Holdings
Arizona
$4K +$4K +1,000 New
GTC
32
Ghost Tree Capital
New York
-$1.8M -473,562 Closed
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
-$311K -81,739 Closed
Russell Investments Group
34
Russell Investments Group
United Kingdom
-$263K -69,351 Closed
Fidelity Investments
35
Fidelity Investments
Massachusetts
-$8K -2,163 Closed
TRCT
36
Tower Research Capital (TRC)
New York
-$7K -1,782 Closed